Recent Articles
Whitehouse Directs FDA, HHS and VA to Expand Psychedelic Research Pathways
The White House moved to accelerate federal handling of psychedelic drugs, including ibogaine, while leaving core approval, scheduling and reimbursement hurdles in place. President Donald Trump on April 18 signed an executive order directing federal agencies to speed review, research, and access pathways for psychedelic drugs, with a focus on serious mental illness and veteran […]
By Joe Moore
Filter
The Place of Incilius Alvarius Within Indigenous Society
A look at Sonoran Desert toad medicine through the lens of indigenous sovereignty, ecological strain,…
By Tricia Eastman
Gov. Spencer Cox Signs Utah’s H.B. 390 Into Law, Authorizing Psychedelic Research for Veterans With PTSD
Utah Gov. Spencer Cox has signed H.B. 390 into law, authorizing the Huntsman Mental Health…
By Joe Moore
Senate Bill S.4031 Signals a Federal Turn Toward Psychedelic Medicine
Senate bill S.4031 would establish VA Centers of Excellence to study psychedelic therapies — including…
By Joe Moore
Colorado’s Ibogaine Bill Could Be a Landmark — If It Respects the Plant’s Roots
HB26-1325 would create a state-supported ibogaine research program to study addiction and PTSD treatment, including…
By Joe Moore
Navigating Colorado’s Regulated Psychedelic Model: Lessons From the Front Lines
Entering the legal, regulated model of psychedelic therapy was the last thing on my mind…
By Jillian Gordon
Seeing Through the Veil: Why Psychedelic Experiences Often Feel More Real Than Ordinary Life
What if classic psychedelic medicines like psilocybin don’t heal primarily by changing brain chemistry, but…